Trial Profile
Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 05 May 2014 Added association merck sharp and dohme as per NCT
- 15 Nov 2008 New trial record.